Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Bausch + Lomb to buy ‘dry eye' treatment from Novartis in a $2.5 billion deal
09:32am, Friday, 30'th Jun 2023
Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Ba
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
08:00am, Monday, 19'th Jun 2023
Three XIFAXAN® (rifaximin) Research Posters to Be Featured LAVAL, QC / ACCESSWIRE / June 19, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceu
'I don't think we ever go back to where we were' with in-office work: Bausch + Lomb CEO Saunders
08:04am, Monday, 12'th Jun 2023
Brent Saunders, Bausch + Lomb CEO and Roam board chair, joins 'Squawk Box' to discuss the future of work, why remote work is here to stay, and more.
Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
01:49pm, Wednesday, 07'th Jun 2023
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
Why Bausch Health Companies Stock Is Tanking Today
11:50am, Tuesday, 06'th Jun 2023
Today, Bausch Health Company acknowledged the FDA's decision to tentatively approve a generic version of Xifaxan. The company also noted that final approval remains off the table until Oct. 2, 2029.
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
02:34pm, Thursday, 18'th May 2023
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Bausch Health stock soars after company says rival application for generic version of its IBS drug can't be approved until 2029
07:34pm, Wednesday, 17'th May 2023
Bausch Health Cos. Inc. BHC, +24.09% on Wednesday said a U.S. district court stuck with an earlier judgment that prevented an application for a rival generic version of its Xifaxan irritable bowel syn
Options Action: Traders boost Bausch Health stock after patent ruling
06:37pm, Wednesday, 17'th May 2023
Kevin Kelly, Kelly Intelligence CEO, joins CNBC's Melissa Lee and the Options Action traders to discuss bullish bets on Bausch Health.
Why Shares of Bausch Health Soared Wednesday
03:35pm, Wednesday, 17'th May 2023
Bausch could get to keep its patent for an IBS drug for another six years. The drug brought in nearly $400 million in the first quarter.
Bausch Health: Bullish On Long-Term Prospects, Awaiting Subsiding Headwinds
08:44am, Wednesday, 10'th May 2023
Bausch Health has been through rough times, leading to skepticism among investors. Its investment potential, however, has been on the upswing since 2016, when Joseph Papa took over as CEO.
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
02:27pm, Friday, 05'th May 2023
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
12:12pm, Thursday, 04'th May 2023
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Bausch Health to Announce First-Quarter 2023 Results on May 4
08:00am, Thursday, 13'th Apr 2023
LAVAL, QC / ACCESSWIRE / April 13, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023. Bausch Health will host a conferen
Bausch Health: Full Bausch + Lomb Spin-Off Finally Seems Close
06:17pm, Monday, 27'th Feb 2023
Bausch + Lomb Corporation recently appointed a new high-profile CEO in Brent Saunders. Bausch Health Companies Inc. has hit the internal metrics necessary to justify spinning off more Bausch + Lomb sh
Bausch Health's (BHC) Q4 Earnings & Sales Beat, Shares Up
10:35pm, Friday, 24'th Feb 2023
Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.
